Acting at the FDA's request, the U.S. Marshals Service seized 11 batches of heparin from Celsus Laboratories that were tainted with oversulfated chondroitin sulfate, a substance that imitates the drug's blood-thinning effects. The agency said Celsus' products were made using raw materials from China and that it informed regulators in the EU, Japan and other countries about shipments of the contaminated blood thinner.

Related Summaries